|
Aigner A, Czubayko F.
Ribozym-PEI-Komplexe zur Ausschaltung der Genexpression in Tumoren
BioForum 7-8
(2003)
Baumann F, Preiss R:
Application of liquid chromatography-mass spectrometry in the
determination of oxazaphosphorines and their metabolites.
Anal Chim Acta 492 (2003) 147-156.
Dassow H, Preiss R:
Development of a competitive reverse-transcription polymerase chain
reaction
for quantitative measurement of sulfotransferase subfamily 1A enzyme in
human hepatoma cells.
Anal Biochem 319 (2003) 314-317
Ray R, Cabal-Manzano R, Moser A R, Waldman T, Zipper L M, Aigner A, Byers S W, Riegel A T, Wellstein A.
Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis.
Cancer Res 63 (2003) 8085-8089
Roelle S, Grosse R, Aigner A, Czubayko F,
Gudermann T.
Matrix metalloproteinases 2 and 9 mediate epidermal
growth factor receptor transactivation by gonadotropin-releasing
hormone.
J Biol Chem 278
(2003) 47307-47318
Preiss R:
Grundlagen der Klinischen Pharmakologie.
In: Olthoff D: Arzneimittelanwendungen in der Anästhesie.
Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart (2003) 37-96.
Regenthal R, Preiss R:
Ertapenem (Invanz®).
Arzneiverordnung in der Praxis 4 (2003) 28.
Regenthal R, Preiss R:
Tiotropiumbromid (Spiriva®).
Arzneiverordnung in der Praxis 4 (2003) 30.
Teichert J, Hermann R, Ruus P, Preiss R:
Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid
following oral administration in healthy volunteers.
J Clin Pharmacol 43 (2003) 1257-1267.
Ulbricht U, Brockmann M A, Aigner A,
Müller S, Fillbrandt R, Westphal M, Lamszus K.
Expression and function of the receptor protein
tyrosine phosphatase zeta and its ligand pleiotrophin in human
astrocytomas.
J Neuropathol Exp Neurol 62
(2003) 1265-1275
Zugmaier G, Knabbe C, Aigner A.
Das Mammakarzinom - Risikofaktoren, Prognose und medikamentöse
Therapie
Med Welt 54
(2003) 96-101
|